Newsfile Corp
29 Sept 2026, 11:53 UTC · 43m ago
Verdict
Headline takes no side. We score RHEL +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Filament Health has shipped its PEX010 psilocybin drug candidate to the University of Calgary for the Phase 2 PsiPTSD trial for survivors of intimate partner violence.
Newpress release dated September 29, 2026
More positive than 79% of claims this week
Rhelion owns a portfolio of 78 issued patents across 13 patent families through its acquisition of Filament Health.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 54% of claims this week
PEX010 is currently supplied in 1, 5, and 25 mg doses, with a 0.5 mg dose expected to follow.
Newpress release dated September 29, 2026
So whatAdding the 0.5 mg dose increases the precision of dosing protocols for future clinical trials starting in late 2026 or 2027.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company announced the successful shipment of its drug candidate PEX010 for a Phase 2 clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
No price for RHEL right now — the quote feed didn't answer.
RHEL chart →
